These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32795875)

  • 21. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
    Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
    BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
    Candon D; Healy J; Crown J
    Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
    Hannouf MB; Zaric GS; Blanchette P; Brezden-Masley C; Paulden M; McCabe C; Raphael J; Brackstone M
    Pharmacogenomics J; 2020 Feb; 20(1):27-46. PubMed ID: 31130722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
    Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.
    Retèl VP; Joore MA; van Harten WH
    Breast Cancer Res Treat; 2012 Jan; 131(2):627-36. PubMed ID: 21947677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scenario drafting to anticipate future developments in technology assessment.
    Retèl VP; Joore MA; Linn SC; Rutgers EJ; van Harten WH
    BMC Res Notes; 2012 Aug; 5():442. PubMed ID: 22894140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
    Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
    Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
    Chen E; Tong KB; Malin JL
    Am J Manag Care; 2010 Dec; 16(12):e333-42. PubMed ID: 21291290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
    Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
    Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility analysis of 21-gene assay for node-positive early breast cancer.
    Masucci L; Torres S; Eisen A; Trudeau M; Tyono I; Saunders H; Chan KW; Isaranuwatchai W
    Curr Oncol; 2019 Oct; 26(5):307-318. PubMed ID: 31708649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
    Kondo M; Hoshi SL; Yamanaka T; Ishiguro H; Toi M
    Breast Cancer Res Treat; 2011 Jun; 127(3):739-49. PubMed ID: 21082239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.